290 likes | 523 Views
Syncope. Definition: Sudden transient loss of conciousness and postural tone with subsequent spontaneous recovery.. Syncope - Epidemiology. 1% of hospital admissions3% of ER visits6% annual incidence in the elderlyUpto 50% of young adults have history of isolated LOC Annual cost $800 M
E N D
1. Evaluation and Management of Syncope
2. Syncope Definition:
Sudden transient loss of conciousness and postural tone with subsequent spontaneous recovery.
3. Syncope - Epidemiology 1% of hospital admissions
3% of ER visits
6% annual incidence in the elderly
Upto 50% of young adults have history of isolated LOC
Annual cost $800 M (1999)
Clin Electrophysiol 22:1386,1999
4. Syncope - Prognosis Highest mortality in patients with cardiac cause
Neurally mediated syncope/ medication induced syncope did not increase mortality
Soteriades ES, et al: N Eng J Med 347:878, 2002
5. Causes of Syncope Vascular ( 58 – 62 % ) : Reflex mediated, orthostatic, anatomic
Cardiac ( 10 – 23 % ): Arrhythmias, anatomic
Neurologic/cerebrovascular* ( 0.5 – 5 % )
Metabolic/drugs ( 0 – 2 % )
Psychogenic* ( 0.2 – 1.5 % )
Syncope of unknown origin ( 14 – 18 % )
6. Differential Diagnosis of Syncope
7. Syncope - Clinical Features Suggestive of Specific Causes
8. Syncope – Clinical Features Suggestive of Specific Causes (cont’d )
9. Syncope – Clinical Features Suggestive of Specific Causes ( cont’d )
10. Diagnostic Tests for Syncope
11. Diagnostic Tests for Syncope (cont’d)
12. Sinus Arrest
13. Syncope – Loop Event Recorder
14. Implanted Loop Event Recorder
15. Wide Complex Tachycardia – Loop Event Monitor
16. Head Up Tilt Table Testing
17. Neurally Mediated Syncope Also known as vasovagal syncope.
Syncope in the absence of structural heart disease is most likely neurally mediated.
Head-upright tilt test maximizes venous pooling, sympathetic activation and circulating catecholamines.
Most vasovagal episodes involve both cardioinhibition (drop in heart rate) and vasodepressor response (drop in BP).
19. Drugs Affecting Sinus Node Function Antiarrhythmic Drugs
Amiodarone
Flecainide, propafenone, sotalol
Quinidine, disopyramide, procainamide
Antihypertensives (Sympatholytic)
Alpha-methyldopa, reserpine, clonidine
Beta-Blockers
Miscellaneous
Cimetidine, Lithium, Phenytoin
20. Sinus Node Recovery Time – 1 of 2
21. Sinus Node Recovery Time – 2 of 2
22. Electrophysiologic Recording of AV Block ( 1 of 2 )
23. Electrophysiologic Recording of AV Block ( 2 of 2 )
24. Therapy of Neurocardiogenic Syncope
25. Syncope - Prognosis Highest mortality in patients with cardiac cause
Neurally mediated syncope/ medication induced syncope did not increase mortality
Soteriades ES, et al: N Eng J Med 347:878, 2002
26. Suggested Strategies for Syncope Management
27. Syncope:May be a harbinger of sudden cardiac death Evaluation – purpose is to determine if pt is at increased risk for death
Identify pts with underlying heart disease (ischemic CM, non-ischemic CM, HCM), myocardial ischemia, WPW, genetic diseases (long-QT syndrome, Brugada Syndrome), catecholaminergic polymorphic VT
28. AHA/ACCF Scientific Statement on the Evaluation of Syncope
29. AHA/ACCF Scientific Statement on the Evaluation of Syncope, continued…
30. Diagnostic Evaluation of Syncope